How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Cell and Gene Therapy Market
- By Therapy Type: Chimeric Antigen Receptor T-cell (CAR-T) Therapy, Gene Editing Therapy, Gene Replacement Therapy, T-cell Receptor (TCR) Therapy, Oncolytic Virus Therapy
- By Cell Source: Autologous Cells, Allogeneic Cells, Induced Pluripotent Stem Cells (iPSCs), Hematopoietic Stem Cells (HSCs), Mesenchymal Stem Cells (MSCs)
- By Application Area: Oncology, Rare Genetic Disorders, Neurological Disorders, Cardiovascular Diseases, Autoimmune Diseases
- By Vector Type: Lentiviral Vectors, Adeno-Associated Viral (AAV) Vectors, Retroviral Vectors, Non-viral Vectors, Adenoviral Vectors
- By End User: Hospitals and Clinics, Specialty Clinics, Research Institutes, Contract Manufacturing Organizations (CMOs), Academic and Government Research Centers
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Chimeric Antigen Receptor T-cell (CAR-T) Therapy leads By Therapy Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 307 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.186 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.194 →
Full report · locked preview
Everything inside the Cell and Gene Therapy Market report
A complete, evidence-based study - 12 chapters and 129 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Companies profiled
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Novartis AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Gilead Sciences
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Inc. (Kite Pharma)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Bristol-Myers Squibb (Juno Therapeutics)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Bluebird Bio Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Sangamo Therapeutics Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Adaptimmune Therapeutics plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Cellectis S.A.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Allogene Therapeutics Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Legend Biotech Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Poseida Therapeutics Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Fate Therapeutics Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Sorrento Therapeutics Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Immatics Biotechnologies GmbH
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Atara Biotherapeutics Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Celyad Oncology SA
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Chimeric Antigen Receptor T-cell (CAR-T) Therapy56.9
- Gene Editing Therapy9.0
- Gene Replacement Therapy9.1
- T-cell Receptor (TCR) Therapy13.0
- Oncolytic Virus Therapy11.9
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Novartis AG21.0
- Gilead Sciences18.5
- Inc. (Kite Pharma)6.9
- Bristol-Myers Squibb (Juno Therapeutics)5.2
- Bluebird Bio Inc.10.4
- Sangamo Therapeutics Inc.9.9
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.3
- Europe22.7
- Asia Pacific21.2
- Latin America14.4
- Middle East and Africa10.4
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Novartis AG | 88 | 86 | 87 | 87 | 74 | 98 | 87 |
| Gilead Sciences | 91 | 85 | 72 | 68 | 84 | 81 | 80 |
| Inc. (Kite Pharma) | 84 | 86 | 83 | 80 | 67 | 78 | 80 |
| Bristol-Myers Squibb (Juno Therapeutics) | 75 | 78 | 57 | 73 | 78 | 63 | 71 |
| Bluebird Bio Inc. | 73 | 68 | 58 | 63 | 54 | 63 | 63 |
| Sangamo Therapeutics Inc. | 46 | 49 | 58 | 57 | 57 | 55 | 54 |
| Adaptimmune Therapeutics plc | 62 | 53 | 47 | 55 | 51 | 56 | 54 |
| Cellectis S.A. | 54 | 51 | 51 | 38 | 40 | 37 | 45 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Novartis AG
- Gilead Sciences
- Inc. (Kite Pharma)
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Novartis AG | ◐ | ✓ | ✓ | ✓ | ◐ | ◐ |
| Gilead Sciences | ◐ | ✓ | ◐ | ◐ | ◐ | ✓ |
| Inc. (Kite Pharma) | ✓ | ✓ | ✓ | ◐ | ✓ | ✓ |
| Bristol-Myers Squibb (Juno Therapeutics) | ◐ | ◐ | ◐ | ◐ | ◐ | ◐ |
| Bluebird Bio Inc. | ◐ | ◐ | ◐ | ◐ | ◐ | ◐ |
| Sangamo Therapeutics Inc. | − | − | ◐ | − | ◐ | − |
| Adaptimmune Therapeutics plc | ◐ | ◐ | − | − | − | ◐ |
| Cellectis S.A. | ◐ | ◐ | ◐ | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Challenger1
Strong scale, closing on the leaders.
Contender1
Focused players with pockets of strength.
Niche3
Specialists in a single segment or region.
Go-to-market strategy
Land Therapy Type in North America, then scale across Cell and Gene Therapy Market — a $264M beachhead inside a $4.14B market.
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Chimeric Antigen Receptor T-cell (CAR-T) Therapy
Best fit — highest urgency & budget in Therapy Type.
Gene Editing Therapy
Strong fit — clear ROI and a fast path to value.
Gene Replacement Therapy
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Therapy Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Cell Source & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Application Area
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Positioning & messaging
§GTM 2 · p.194 →For Therapy Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Cell and Gene Therapy Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Investment thesis
Cell and Gene Therapy Market is a durable-growth opportunity — $7.66B by 2033, compounding at 7.4%.
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →7.4% CAGR
Demand compounds through 2033, outpacing GDP across Therapy Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Therapy Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →Return scenarios (2033 market value)
Fig. 6 · p.22 →Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Cell Source optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Cell and Gene Therapy Market — a $7.88B market by 2033. Plan: grow share from 7.7% to 16.0%.
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.7% | 16.0% | At risk |
| Revenue | $577M | $1.26B | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 30.2% | 41.0% | On track |
| Customer retention | 85.1% | 94.7% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →Lead segment
Win in Therapy Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
Adjacency
Build Cell Source capability
A defensible second engine — invest in Cell Source to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Therapy Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Cell Source
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $140M capacity & capability investment
- Greenlight bolt-on M&A in Cell Source
- Authorise North America expansion plan
- Fund R&D program for Therapy Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossOn track
- Input-cost & supply riskAt risk
- Regulatory / policy changeBehind
- Execution & talentOn track
Sales deck · value proposition
Win the Cell and Gene Therapy Market conversation — a $8.40B market you can size, segment and defend in minutes.
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Therapy Type
Goal Grow share in Therapy Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →The business case (ROI)
Fig. 2 · p.9 →Why buyers trust it (proof points)
§1.3 · p.12 →Coverage includes
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Cell and Gene Therapy Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
Your report is ready to access
Cell and Gene Therapy Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Cell and Gene Therapy Manufacturing Services Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportCell and Gene Therapy Manufacturing Quality Control Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportCell and Gene Therapy Manufacturing Isolators Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportCell and Gene Therapy Isolator Market
Market size, share, segmentation and regional forecast.
$765M market · 2025 base year
View reportCell and Gene Therapy Drug Delivery Devices Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportCell And Gene Therapy Clinical Trial Market
Market size, share, segmentation and regional forecast.
$674M market · 2025 base year
View reportCell and Gene Therapy Bioassay Services Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportCell and Gene Supply Chain Solutions Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportVitamin D Ingredient Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportCell and Advanced Therapies Supply Chain Management Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportCell Analysis Systems Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportCell Analysis Solution Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy